Document Detail

Inhaled salbutamol for wheezy infants: a randomised controlled trial.
MedLine Citation:
PMID:  10799426     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Salbutamol is frequently used as a bronchodilator for infants who wheeze. Many single dose studies have questioned its effectiveness. AIMS: To investigate the response of wheezy infants to salbutamol over an extended time period in order to elucidate either symptomatic relief or a protective effect. METHODS: Eighty infants under 1 year, with persistent or recurrent wheeze and a personal or family history of atopy, were recruited to a randomised, double blind, cross over, placebo controlled trial. Salbutamol (200 microg three times daily) or placebo were administered regularly over two consecutive treatment periods of four weeks via a spacer and mask. Symptoms of wheeze and cough were recorded in a diary. At the end of the study pulmonary function tests were performed before and after salbutamol (400 microg). RESULTS: Forty eight infants completed the diary study; 40 infants underwent pulmonary function testing. No difference in mean daily symptom score was observed between the salbutamol and placebo periods. There was no difference in the number of symptom free days. Compliance and forced expiratory flows remained unchanged and resistance increased following salbutamol. There was no relation between the response measured by symptom score or pulmonary function in individual patients. CONCLUSION: In wheezy infants with an atopic background, there was no significant beneficial effect of salbutamol on either clinical symptoms or pulmonary function. Clinical effects could not be predicted from pulmonary function tests. Salbutamol cannot be recommended as the bronchodilator of choice in this age group.
R J Chavasse; Y Bastian-Lee; H Richter; T Hilliard; P Seddon
Related Documents :
2191696 - The transitional circulation: physiology and anesthetic implications.
2976816 - Drug-induced paralysis (muscle relaxant) therapy in the mechanically ventilated neonate.
23927126 - Phonological theory informs the analysis of intonational exaggeration in japanese infan...
22970676 - Incorporating speech-language pathology within australian neonatal intensive care units.
20620626 - Etiology and one-year follow-up results of hearing loss identified by screening of newb...
18022446 - Percutaneous cholangiography for the treatment of parenteral nutrition-associated chole...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Archives of disease in childhood     Volume:  82     ISSN:  1468-2044     ISO Abbreviation:  Arch. Dis. Child.     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-05-31     Completed Date:  2000-05-31     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0372434     Medline TA:  Arch Dis Child     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  370-5     Citation Subset:  AIM; IM    
The Royal Alexandra Hospital for Sick Children, Dyke Road, Brighton BN1 3JN, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Albuterol / therapeutic use*
Bronchodilator Agents / therapeutic use*
Cross-Over Studies
Double-Blind Method
Forced Expiratory Flow Rates / drug effects
Hypersensitivity, Immediate / physiopathology,  prevention & control*
Infant, Newborn
Lung Compliance / drug effects
Medical Records
Respiratory Sounds*
Reg. No./Substance:
0/Bronchodilator Agents; 18559-94-9/Albuterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fish oil supplementation improves docosahexaenoic acid status of malnourished infants.
Next Document:  Risk assessment of renal cortical scarring with urinary tract infection by clinical features and ult...